At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 282 enrolled
Drug / intervention
KP415 oral capsuledrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Dose-Optimized, Open-Label Safety Study With KP415 in Children With Attention-Deficit/Hyperactivity Disorder
In Brief
A Phase 3 clinical trial evaluating KP415 oral capsule for ADHD. Completed, enrolled 282 participants across 19 sites.
Detailed Summary
This study is a multicenter, dose-optimized, open-label safety study with KP415 in children with Attention-Deficit/Hyperactivity Disorder (ADHD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsADHD
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedMar 2018
Enrollment StartMar 2018
Primary CompletionJun 2019
Study CompletionJul 2019
TodayJul 2026
First PostedMar 9, 2018
Enrollment StartMar 13, 2018
Primary CompletionJun 20, 2019
Study CompletionJul 9, 2019
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 8.3 years ago
Interventions
KP415 oral capsuledrug
Once-daily oral dose